The project aims to clinically validate ViewMind's technology to study neurocognitive deficiencies in Long COVID patients.
The long-term consequences to an individual of catching COVID need to be considered and better understood. A study in the Lancet of 234K patients showed 33.6% of individuals suffer neurological impacts 6 months after recovery. Long COVID patients with neurological impacts have elevated levels of neuroinflammation. Neuroinflammation has demonstrated a key role in the pathogenesis of Alzheimer's disease and other dementias.
There is a pressing need for these neurocognitive impacts to be better understood with high sensitivity, accessible, non-invasive, affordable solutions that can support evidence-based disease management.
